Palisade Bio (NASDAQ:PALI) Director Robert Jr. Baltera Acquires 10,000 Shares of Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were acquired at an average price of $1.98 per share, for a total transaction of $19,800.00. Following the completion of the acquisition, the director directly owned 366,904 shares of the company’s stock, valued at $726,469.92. This trade represents a 2.80% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Robert Jr. Baltera also recently made the following trade(s):

• On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was bought at an average cost of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Stock Up 3.7%

PALI traded up $0.07 during trading on Tuesday, hitting $2.12. 318,176 shares of the company traded hands, compared to its average volume of 4,084,679. Palisade Bio, Inc. has a one year low of $0.53 and a one year high of $2.86. The stock’s fifty day moving average is $1.91 and its 200 day moving average is $1.91. The firm has a market cap of $367.12 million, a P/E ratio of -2.09 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, equities research analysts forecast that Palisade Bio, Inc. will post -0.25 EPS for the current fiscal year.

Institutional Trading of Palisade Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cetera Investment Advisers bought a new position in Palisade Bio in the 4th quarter worth $25,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Palisade Bio in the 4th quarter worth about $26,000. Virtu Financial LLC bought a new stake in shares of Palisade Bio during the 4th quarter valued at about $28,000. CTC Alternative Strategies Ltd. purchased a new position in shares of Palisade Bio during the first quarter valued at about $31,000. Finally, Atom Investors LP purchased a new position in shares of Palisade Bio during the fourth quarter valued at about $33,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Palisade Bio in a research report on Tuesday, June 30th. Wolfe Research initiated coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective on the stock. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a report on Sunday. Weiss Ratings raised shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Finally, LADENBURG THALM/SH SH upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $8.83.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.